News

Obama: Insufficient data to fast-track Ebola drug

Obama: Insufficient data to fast-track Ebola drug

EBOLA OUTBREAK: U.S. President Barack Obama delivers remarks at the first Leaders Session of the U.S.-Africa Leaders Summit at the State Department in Washington, Aug. 6. Photo: Reuters/Larry Downing

WASHINGTON (Reuters) – President Barack Obama said on Wednesday he lacks enough information to green-light a promising drug to treat the deadly Ebola virus and that the initial response should focus on public health measures to contain the outbreak.

“We’ve got to let the science guide us and I don’t think all the information is in on whether this drug is helpful,” the president said at a media conference. “The Ebola virus both currently and in the past is controllable if you have a strong public health infrastructure in place.”

Public health officials should do all they can to contain the outbreak, and during the course of that process, authorities can assess whether new drugs or treatments can be effective, he said.

“We’re focusing on the public health approach right now, but I will continue to seek information about what we’re learning about these drugs going forward,” he said.

(Reporting By Mark Felsenthal; Editing by Sandra Maler)

Recent Headlines

in Sports, Viral Videos

David Beckham for ‘D&J Briefs’

Fresh
21-overlay5

It's underwear for a man with a great body ... and David Beckham.

in National, Viral Videos

Girl, 4, boards bus for 3 a.m. snack run

16-overlay3

Little Annabelle Ridgeway was determined to get a slushie.

in Entertainment

Trevor Noah set to replace Stewart on ‘Daily Show’

trevornoah

Comedy Central has named Trevor Noah, a 31-year-old comedian from South Africa, as Jon Stewart's replacement.

in Entertainment

‘Home’ tops weekend box office

home

Jennifer Lopez and Rihanna's new animated movie raked in $54 million this weekend.

in Entertainment

Hugh Jackman is done with ‘Wolverine’

Hugh Jackman

Jackman has played Wolverine for the past 15 years, including two stand-alone sequels.